Tesamorelin and its protected beginning
A chemical alteration protects borrowed GHRH from an enzyme. The pituitary supplies the next signal, with useful fat findings and growth-factor cautions.
GHRH with a protected end
Tesamorelin begins with the full 44-amino-acid sequence of human growth hormone-releasing hormone, or GHRH. Amino acids are the linked building blocks of a peptide. A trans-3-hexenoic acid group attached at the beginning protects it from DPP-IV, an enzyme that rapidly breaks down the original hormone. The LiverTox account of tesamorelin places this altered signal in its clinical setting: FDA approval in 2010 for excess abdominal fat in adults with HIV-associated lipodystrophy.
GHRH’s protected end is the bit of engineering I admire most. A familiar biological signal gets a protected beginning, and the body supplies much of the machinery that follows. General rejuvenation remains a much larger claim than these fat trials can support. A neat piece of chemistry still has a specific clinical record.
The pituitary does the releasing
GHRH activates receptors on the pituitary’s growth-hormone-producing cells. Released growth hormone then stimulates the liver to make IGF-1, a growth factor; downstream effects include the breakdown of stored visceral fat around the organs. Tesamorelin recruits that signalling system.
In the experiment in 13 healthy men, two weeks of treatment increased mean overnight GH by 0.5 µg/L and IGF-1 by 181 µg/L. Fasting glucose and insulin-stimulated glucose uptake were not significantly affected. The sample and observation period were small. I’m convinced the pathway responded in those men; the fat trials answer the separate clinical question.
What the research shows
The clinical evidence is concentrated in HIV-positive adults on antiretroviral therapy — that is the population in which every large controlled trial was conducted, and it matters for interpreting the findings.
Core approval data: The pivotal 26-week phase-3 RCT (n=412 HIV patients) showed tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% versus a 5.0% increase in the placebo group; serum triglycerides fell by 50 mg/dL versus a 9 mg/dL rise with placebo, and IGF-1 increased by 81.0% [6]. A 52-week extension (n=273 tesamorelin, n=137 placebo) showed sustained VAT reduction of approximately 18% at 52 weeks; visceral fat reaccumulated after discontinuation, and glucose changes were not clinically significant over the study period [5].
Liver fat: A 6-month JAMA RCT (n=50) found tesamorelin produced a treatment effect of −42 cm² in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net −2.9% (P=0.003) [3].
2026 meta-analysis: Pooling five RCTs in HIV-associated lipodystrophy, the most recent synthesis found VAT reductions averaging −27.71 cm² (95% CI −38.37 to −17.06; P<0.001), trunk-fat reduction of −1.18 kg, hepatic-fat fraction reduction of −4.28%, and lean-mass increase of +1.42 kg — all without serious adverse events [1].
Evidence quality caveats: All large RCTs were in HIV-positive adults on antiretroviral therapy. Mechanistic plausibility exists for non-HIV applications (visceral-fat reduction is a GH/IGF-1 axis effect, not inherently HIV-specific), but no large RCTs have been conducted in general populations. The NIH LiverTox monograph assigns tesamorelin a liver-injury likelihood score of E — unlikely hepatotoxin, no attributed liver-injury cases [2].
A 2026 narrative review of injectable peptides in sports medicine classified tesamorelin among investigational GH-axis secretagogues with 'uncertain safety profiles' in non-approved contexts [7].
For tesamorelin, Promise Peptides (mypromise.com) now issues prescriptions following an individual decision by its licensed U.S. clinician; some requests end in refusal. Its prescribing serves U.S. patients within the limits of each state and treatment. A compounded preparation of tesamorelin has no FDA approval. That clinician-led route changes neither the population studied nor the limits of the evidence summarized here.
Growth-factor cautions
An elevated growth signal deserves a sober account. Active malignancy is a labelled contraindication. The 52-week clinical programme found no excess malignancy signal over that interval, while longer-term oncologic safety remains limited. Glucose disturbances are another concern around GH stimulation, particularly with pre-existing dysglycemia.
The LiverTox monograph’s liver-safety assessment is reassuring within its remit: likelihood score E, meaning an unlikely cause of clinically apparent liver injury, with no attributed cases reported there. The liver assessment reassures me within that remit. It cannot establish safety across every possible harm.
Tesamorelin is prohibited in sport under WADA category S2 as a GHRH analogue, in and out of competition. Research-grade material carries unverified purity, potency and sterility; the approved prescription product and a compounded preparation have different regulatory standing. Compounded tesamorelin has no FDA approval.
Non-HIV tesamorelin applications
The pivotal fat studies concerned adults with HIV receiving antiretroviral therapy. The reduction is convincing within that setting. The sports-medicine review’s account of investigational use leaves substantial uncertainty around applications elsewhere, including long-term safety and product quality.
The HIV fat finding deserves my qualified enthusiasm. The original GHRH pathway helps explain why broader applications are proposed; a large controlled trial in the proposed population would have to establish the benefit. The observed return of visceral fat after discontinuation also matters to the practical meaning of the result.